---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255200"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:08:30.788262+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

## Summary
- Completed successful end-of-Phase 2 meeting with FDA for bitopertin in EPP, reaching alignment on all proposed study parameters with potential for accelerated approval.
- Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in NDD-CKD patients with anemia at ASN Kidney Week 2024.
- Ended Q3 2024 with $487M cash; closed $200M non-dilutive debt financing with Hercules Capital in November 2024.
- Net loss was $26.6M for Q3 2024, compared to $14.1M for same period in 2023.
- Appointed Steve Caffé as Chief Regulatory Officer and Rahul Kaushik as Chief Technical Officer.

## SEC filing metadata
- accession: 0001193125-24-255200
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/0001193125-24-255200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312524255200/d911918d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255200
- JSON: https://secwatch.observer/filing/0001193125-24-255200.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.